Zavegepant

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 76 publications

Quality by design based development and optimization of a thermoreversible in situ intranasal gel of zavegepant for nose to brain delivery in migraine therapy.

Quality by design based development and optimization of a thermoreversible in situ intranasal gel of zavegepant for nose to brain delivery in migraine therapy.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: March 03, 2026

Zavegepant and lactation: What the pharmacokinetic data suggests.

Zavegepant and lactation: What the pharmacokinetic data suggests.

Journal: Headache

Published: January 13, 2026

Knowledge Discovery and Drug-Repurposing Framework for Pancreatic Ductal Adenocarcinoma: Molecular Networking and Computational Docking.

Knowledge Discovery and Drug-Repurposing Framework for Pancreatic Ductal Adenocarcinoma: Molecular Networking and Computational Docking.

Journal: Computational and structural biotechnology journal

Published: December 17, 2025

Cost-effectiveness analysis of ubrogepant, rimegepant, and zavegepant for acute migraine treatment vs usual care.

Cost-effectiveness analysis of ubrogepant, rimegepant, and zavegepant for acute migraine treatment vs usual care.

Journal: The American journal of managed care

Published: November 25, 2025

Early Experience Treating Vestibular Migraine With Small Molecule CGRP Antagonists.

Early Experience Treating Vestibular Migraine With Small Molecule CGRP Antagonists.

Journal: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery

Published: October 22, 2025

Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data.

Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data.

Journal: Headache

Published: October 13, 2025

Gepants: targeting the CGRP pathway for migraine relief.

Gepants: targeting the CGRP pathway for migraine relief.

Journal: Frontiers in pharmacology

Published: September 18, 2025

Drug Repurposing Identifies Natamycin and Avacopan as Urease-Targeted Therapeutic Candidates Against Helicobacter pylori.

Drug Repurposing Identifies Natamycin and Avacopan as Urease-Targeted Therapeutic Candidates Against Helicobacter pylori.

Journal: Helicobacter

Published: September 13, 2025

The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies.

The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies.

Journal: Headache

Published: September 09, 2025

Patient-Reported Outcomes During the Acute Treatment of Migraine with Zavegepant Nasal Spray: Results from a 52-Week, Open-Label Study.

Patient-Reported Outcomes During the Acute Treatment of Migraine with Zavegepant Nasal Spray: Results from a 52-Week, Open-Label Study.

Journal: Pain and therapy

Published: July 15, 2025

Safety analysis of gepants for migraine treatment: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.

Safety analysis of gepants for migraine treatment: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.

Journal: Headache

Published: July 08, 2025

Integrating gepants into clinical practice for the acute treatment of migraine.

Integrating gepants into clinical practice for the acute treatment of migraine.

Journal: Headache

Published: June 11, 2025

Showing 1-12 of 76

Last Updated: 06/30/2026